Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 10—October 2010

Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA

Scott K. HeysellComments to Author , Jane L. Moore, Suzanne J. Keller, and Eric R. Houpt
Author affiliations: Author affiliations: University of Virginia, Charlottesville, Virginia, USA (S.K. Heysell, E.R. Houpt); Virginia Department of Health, Richmond, Virginia, USA (J.L. Moore, S.J. Keller)

Main Article

Table 2

Comparison of median serum concentration at 2 hours after medication administration as estimate of peak serum concentration levels and expected range, therapeutic drug monitoring, Virginia, USA, March 1, 2007–May 1, 2009*

Medication Median serum concentration, µg/mL (IQR) Expected serum concentration range, µg/mL
Daily 1.9 (1.1–3.5) 3–6
9.8 (2.8–11.2)
Rifampin daily and/or biweekly
7.4 (2.5–11.4)
2.5 (1.7–3.2)
Pyrazinamide† 28.1 (26.5–33.2) 20–50

*IQR, interquartile range.
†All patients with therapeutic drug monitoring levels obtained for ethambutol and pyrazinamide were taking weight-based daily doses of these medications.

Main Article

Page created: September 07, 2011
Page updated: September 07, 2011
Page reviewed: September 07, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.